NASDAQ:PPHM
Delisted

Peregrine Pharmaceuticals Inc. Fund Forecast

$4.22
+0 (+0%)
At Close: Jan 22, 2018
RSI low/high Values: [ 20 - 80 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.

Peregrine Pharmaceuticals Inc. fund price down 0% on Monday
(Updated on Jan 22, 2018)

Sell candidate since Jan 04, 2018 Gain 0.72% PDF

No changes to the price of Peregrine Pharmaceuticals Inc. fund on the last trading day (Monday, 22nd Jan 2018). During the last trading day the fund fluctuated 0% from a day low at $4.22 to a day high of $4.22. The price has been going up and down for this period, and there has been a 0% change for the last 2 weeks.

The fund lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the fund is expected to fall -7.76% during the next 3 months and, with a 90% probability hold a price between $3.32 and $4.76 at the end of this 3-month period.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

PPHM Signals & Forecast

Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Some negative signals were issued as well, and these may have some influence on the near short-term development. The Peregrine Pharmaceuticals Inc. fund holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $4.22 and $4.37. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Friday, January 19, 2018, and so far it has fallen 0%. Further fall is indicated until a new bottom pivot has been found. Volume fell on the last day without any changes to the price. This does not cause any direct divergence but may be an early warning and a possible "turning point". The very low volume increases the risk and reduces the other technical signals issued.

Support, Risk & Stop-loss for Peregrine Pharmaceuticals Inc. fund

Peregrine Pharmaceuticals Inc. finds support from accumulated volume at $4.20 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

In general the fund tends to have very controlled movements and therefore the general risk is considered very low. However, be aware of low or falling volume and make sure to keep an eye on the fund During the last day, the fund moved $0 between high and low, or 0%. For the last week the fund has had daily average volatility of 0%

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (PPHM) For The Upcoming Trading Day Of Tuesday 23rd

For the upcoming trading day on Tuesday, 23rd we expect Peregrine Pharmaceuticals Inc. to open at $4.22, and during the day (based on 14 day Average True Range), to move between $4.10 and $4.34, which gives a possible trading interval of +/-$0.117 (+/-2.77%) up or down from last closing price. If Peregrine Pharmaceuticals Inc. takes out the full calculated possible swing range there will be an estimated 5.54% move between the lowest and the highest trading price during the day.

Since the stock is closer to the support from accumulated volume at $4.20 (0.47%) than the resistance at $4.27 (1.18%), our systems sees the trading risk/reward intra-day as attractive and believe profit can be made before the stock reaches first resistance..

Is Peregrine Pharmaceuticals Inc. fund A Buy?

Peregrine Pharmaceuticals Inc. holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this fund.

Current score: -3.640 Sell Candidate Unchanged

Predicted Opening Price for Peregrine Pharmaceuticals Inc. of Tuesday, January 23, 2018

Fair opening price January 23, 2018 Current price
$4.22 ( 0%) $4.22

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for PPHM

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 4.22 .
R2 4.22 .
R1 4.22 .
Current price: 4.22
Support S1 4.22 .
S2 4.22 .
S3 4.22 .

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 4.56 8.06 %
R2 4.35 3.08 %
R1 4.27 1.18 %
Current price 4.22
Support S1 4.20 -0.474%
S2 4.11 -2.61%
S3 4.02 -4.74%

FAQ

What is the symbol for Peregrine Pharmaceuticals Inc. Fund and on which exchange is it traded?
The symbol for Peregrine Pharmaceuticals Inc. is PPHM and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Peregrine Pharmaceuticals Inc. Fund?
Peregrine Pharmaceuticals Inc. holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this fund.

How to buy Peregrine Pharmaceuticals Inc. Fund?
Peregrine Pharmaceuticals Inc. Fund can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Peregrine Pharmaceuticals Inc. Fund.

What's the current price of Peregrine Pharmaceuticals Inc. Fund?
As of the end of day on the 2018-01-22, the price of an Peregrine Pharmaceuticals Inc. (PPHM) share was $4.22.

What is the 52-week high and low for Peregrine Pharmaceuticals Inc. Fund?
The 52-week high for Peregrine Pharmaceuticals Inc. Fund is $5.78 and the 52-week low is $1.97.
Click to get the best stock tips daily for free!

About Peregrine Pharmaceuticals Inc.

Peregrine Pharmaceuticals, Inc., a biopharmaceutical company, researches and develops monoclonal antibodies for the treatment of cancer in the United States. ItÂ’s lead immunotherapy candidate bavituximab, a monoclonal antibody that targets and binds to phosphatidylserine. The company also provides integrated current good manufacturing practices services from cell line development to commercial bio manufacturing for its third-party customers. In ... PPHM Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT